NMDA glutamate receptor polymorphisms modulate antipsychotic-induced hyperprolactinemia in schizophrenia; Progress in Neuro-Psychopharmacology and Biological Psychiatry; Vol. 143

Podrobná bibliografie
Parent link:Progress in Neuro-Psychopharmacology and Biological Psychiatry.— .— Amsterdam: Elsevier Science Publishing Company Inc.
Vol. 143.— 2025.— Article number 111569, 9 p.
Další autoři: Fedorenko O. Yu. Olga Yurievna, Poltavskaya E. Evgeniya, Kornetova E. G. Elena Georgievna, Freidin M. B. Maxim, Bocharova A. V. Anna Vladimirovna, Boyko A, S, Anastasiya Sergeevna, Stepanov V. A. Vadim Anatoljevich, Bokhan N. A. Nikolay Aleksandrovich, Ivanova S. A. Svetlana Aleksandrovna, Strelnikov K. Kuzma
Shrnutí:Title screen
Dopamine receptor inhibition underlies both the therapeutic and adverse effects of antipsychotics, but the mechanisms modulating these effects in patients with schizophrenia remain incompletely understood. Hyperprolactinemia (HPRL), a direct consequence of D2 dopamine receptor blockade, provides a unique clinical model to investigate how genetic variation in glutamatergic signaling influences the downstream effects of dopaminergic disruption. We hypothesized that polymorphisms in GRIN2A and GRIN2B, encoding NMDA glutamate receptor subunits, modify the neuroendocrine consequences of dopamine receptor inhibition. By studying antipsychotic-induced HPRL, we aimed to demonstrate that NMDA receptor genetic variants shape the functional outcomes of dopaminergic perturbation
Текстовый файл
AM_Agreement
Jazyk:angličtina
Vydáno: 2025
Témata:
On-line přístup:https://doi.org/10.1016/j.pnpbp.2025.111569
Médium: Elektronický zdroj Kapitola
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=684627

Podobné jednotky